Can Avastin’s Shortcomings Open the Door for Del Mar Pharmaceuticals?

The effectiveness of Genentech and Roche’s (RHHBY.OB) glioblastoma multiforme (GBM) treatment, Avastin, has recently been challenged raising concerns from physicians and patients alike that a huge void in patient care can develop if the FDA decides to revoke Avastin’s approval for treating GBM.

Read more »

OneMedRadio: Del Mar Pharmaceuticals CEO Discusses the Public Market, Glioblastoma and Orphan Drugs

Vancouver-based DelMar Pharmaceuticals [DMPI] is developing new drug candidates targeting orphan cancer indications representing market opportunities in the $100s of millions in North America and potentially billions of dollars worldwide. Promising data announced in 2012 with follow ups scheduled at various healthcare conferences this year coincided with the company’s recent listing on the OTCQB, which commenced Q1-2013. OneMedRadio spoke with the Del Mar CEO about these milestones.

Read more »

Del Mar Pharmaceuticals Plans Clinical Trials for GBM Treatment

DMP estimates that the market for treating GBM patients post front-line therapy exceeds US$200 million annually in North America.

Read more »

It’s So Hard To Say Goodbye: The Exit Strategy

Parting is such sweet sorrow when building a company from infancy and then letting go to see it spread its wings. Planning a proper exit strategy is crucial and not just when referring to love and war.

Read more »

Del Mar Pharmaceuticals Is Fighting Cancer One Molecule At A Time

Del Mar Pharmaceuticals was recently added to the roster of presenting companies at OneMedForum NY 2011.

Read more »